Actaea Cimicifuga Root Arnica Angustifolia Flower

證據等級: L5

預測適應症: 0 個

Multi-Component Homeopathic Preparation: Insufficient Data for Repurposing Prediction

One-Sentence Summary

This submission contains a 9-ingredient homeopathic/herbal combination product (including Actaea cimicifuga, Arnica, Bryonia alba, Hypericum perforatum, Nux vomica, and Rhus toxicodendron) with no registered brand name, no US market authorization, and no DrugBank identifier on file. The TxGNN model did not generate any repurposing predictions for this compound — most likely because the multi-ingredient string could not be matched to a single node in the knowledge graph. As a result, no evidence-based new indication recommendation can be made at this time.

Quick Overview

Item	Content
Original Indication	Not available — no US license found
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only) — effectively below L5: no prediction was generated
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN prediction is available for this submission. The most likely technical reason is that the drug identifier submitted to the pipeline is a multi-ingredient free-text string rather than a single INN or DrugBank ID. The TxGNN knowledge graph indexes individual drug nodes; a 9-component string does not map to any node, so the model produces no output.

Individually, several of the constituents are pharmacologically active and well-studied:

Hypericum perforatum (St. John’s Wort) has documented inhibitory effects on serotonin, dopamine, and norepinephrine reuptake and is the most evidence-rich ingredient in the combination.
Toxicodendron radicans (Rhus tox) and Bryonia alba are classical homeopathic remedies associated with musculoskeletal and rheumatic complaints; their mechanisms at homeopathic dilutions remain scientifically unvalidated.
Strychnos nux-vomica and Strychnos ignatii both contain strychnine and brucine; at pharmacological doses these are glycine-receptor antagonists with CNS effects, but classical homeopathic use is at ultra-dilute levels where receptor activity is negligible.
Arnica angustifolia is used topically and in low-dilution preparations for bruising and inflammation (helenalin sesquiterpene lactones).

Without a unified MOA, a single original indication, or a TxGNN score to anchor the analysis, no mechanistic bridge to a new indication can be drawn at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered.

(No predicted indication was returned; no trial search was scoped.)

Literature Evidence

Currently no related literature available.

(Awaiting a valid TxGNN prediction before scoping literature review.)

US Market Information

This compound has no US FDA authorizations on record. The TFDA query returned zero results, and total license count is 0.

Safety Considerations

Please refer to the package insert for safety information.

Note for reviewers: Two blocking data gaps were flagged in this Evidence Pack:

DG001 (Blocking) — No package insert warnings or contraindications available. This prevents S1 safety screening from proceeding.

DG002 (High) — No mechanism of action data available. This prevents mechanistic relevance analysis.

Additionally, Hypericum perforatum is a potent CYP3A4/P-gp inducer known to reduce plasma concentrations of antiretrovirals, immunosuppressants, oral contraceptives, and anticoagulants. If this combination product proceeds to any formal evaluation, Hypericum-specific DDI screening is mandatory regardless of the current DDI query result.

Conclusion and Next Steps

Decision: Hold

Rationale: The pipeline was unable to generate a TxGNN prediction because the submitted drug identifier is a multi-ingredient free-text string that does not match any single node in the knowledge graph. Without a prediction score and without US regulatory data, there is no evidence base on which to make a repurposing recommendation.

To proceed, the following is needed:

Resolve drug identity: Determine whether this preparation corresponds to a known branded homeopathic product (e.g., verify if this matches a registered homeopathic complex). If so, obtain the product’s brand name and registration number.
Re-run TxGNN per active ingredient: If repurposing analysis is still desired, run TxGNN individually on each mappable ingredient (particularly Hypericum perforatum, which has a DrugBank entry) and aggregate predictions.
Obtain DrugBank ID: At minimum for Hypericum perforatum (DB00044) to unlock MOA and DDI data.
Remediate DG001: Download and parse the relevant package insert PDF from the TFDA website to populate warnings and contraindications before any safety screening.
Clarify scope: Confirm whether the intended evaluation target is the combination product or an individual lead ingredient. Homeopathic multi-ingredient preparations with no INN are generally outside the standard drug repurposing pipeline and may require a bespoke analytical pathway.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.